Dadachova E, Bouzahzah B, Zuckier L S, Pestell R G
Department of Nuclear Medicine, Albert Eistein College of Medicine, Bronx, NY, USA.
Nucl Med Biol. 2002 Jan;29(1):13-8. doi: 10.1016/s0969-8051(01)00279-7.
The sodium-iodide symporter (NIS), which transports iodine into the cell, is expressed in thyroid tissue and was recently found to be expressed in approximately 80% of human breast cancers but not in healthy breast tissue. These findings raised the possibility that therapeutics targeting uptake by NIS may be used for breast cancer treatment. To increase the efficacy of such therapy it would be ideal to identify a radioactive therapy with enhanced local emission. The feasibility of using the powerful beta-emitting radiometal (188)Re in the form of (188)Re-perrhenate was therefore compared with 131I for treatment of NIS-expressing mammary tumors. In the current studies, using a xenografted breast cancer model induced by the ErbB2 oncogene in nude mice, (188)Re-perrhenate exhibited NIS-dependent uptake into the mammary tumor. Dosimetry calculations in the mammary tumor demonstrate that (188)Re-perrhenate is able to deliver a dose 4.5 times higher than (131)I suggesting it may provide enhanced therapeutic efficacy.
钠-碘同向转运体（NIS）负责将碘转运到细胞内，它在甲状腺组织中表达，最近发现约80%的人类乳腺癌组织中也有表达，而在健康乳腺组织中不表达。这些发现提示，针对NIS摄取的治疗方法可能用于乳腺癌治疗。为提高此类疗法的疗效，理想的做法是找到一种局部发射增强的放射性疗法。因此，将以高锝酸盐形式存在的强β发射放射性金属铼（188Re）与131I用于治疗表达NIS的乳腺肿瘤的可行性进行了比较。在当前研究中，利用在裸鼠中由ErbB2癌基因诱导的异种移植乳腺癌模型，高锝酸铼（188Re）显示出对乳腺肿瘤的NIS依赖性摄取。乳腺肿瘤的剂量学计算表明，高锝酸铼（188Re）能够提供比131I高4.5倍的剂量，这表明它可能具有更强的治疗效果。
